Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurie H Sehn

Showing results (1-10 of 198) with videos related to

Pageof 20
Sort By:
Leukemia & Lymphoma|October 29, 2009
Early detection of patients with poor risk diffuse large B-cell lymphomaLaurie H Sehn
Hematology. American Society of Hematology. Education Program|November 25, 2006
Optimal use of prognostic factors in non-Hodgkin lymphomaLaurie H Sehn
Hematology. American Society of Hematology. Education Program|December 13, 2012
Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphomaLaurie H Sehn
Hematology. American Society of Hematology. Education Program|December 4, 2016
Novel agents in follicular lymphoma: choosing the best targetLaurie H Sehn
Cancer Journal (Sudbury, Mass.)|September 26, 2012
Chemotherapy alone for localized diffuse large B-cell lymphomaLaurie H Sehn
Blood|March 3, 2022
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?Jason Westin, Laurie H Sehn
Blood|July 14, 2022
Developing a classification of hematologic neoplasms in the era of precision medicineMario Cazzola, Laurie H Sehn
Blood|August 14, 2025
Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?Carla Casulo, Laurie H Sehn
Hematology/Oncology Clinics of North America|November 28, 2016
Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?Eva Giné, Laurie H Sehn
Best Practice & Research. Clinical Haematology|September 15, 2018
Management of relapsed/refractory DLBCLClémentine Sarkozy, Laurie H Sehn
Pageof 20

Showing results (1-10 of 198) with videos related to

Sort By:
Pageof 20
Leukemia & Lymphoma|October 29, 2009
Early detection of patients with poor risk diffuse large B-cell lymphomaLaurie H Sehn
Hematology. American Society of Hematology. Education Program|November 25, 2006
Optimal use of prognostic factors in non-Hodgkin lymphomaLaurie H Sehn
Hematology. American Society of Hematology. Education Program|December 13, 2012
Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphomaLaurie H Sehn
Hematology. American Society of Hematology. Education Program|December 4, 2016
Novel agents in follicular lymphoma: choosing the best targetLaurie H Sehn
Cancer Journal (Sudbury, Mass.)|September 26, 2012
Chemotherapy alone for localized diffuse large B-cell lymphomaLaurie H Sehn
Blood|March 3, 2022
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?Jason Westin, Laurie H Sehn
Blood|July 14, 2022
Developing a classification of hematologic neoplasms in the era of precision medicineMario Cazzola, Laurie H Sehn
Blood|August 14, 2025
Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?Carla Casulo, Laurie H Sehn
Hematology/Oncology Clinics of North America|November 28, 2016
Diffuse Large B-Cell Lymphoma: Should Limited-Stage Patients Be Treated Differently?Eva Giné, Laurie H Sehn
Best Practice & Research. Clinical Haematology|September 15, 2018
Management of relapsed/refractory DLBCLClémentine Sarkozy, Laurie H Sehn
Pageof 20